The Innovation Blueprint
Heart failure is still one of the world’s leading causes of death, yet investment and innovation continue to lag behind cancer research. Ayla Annac explains why large-scale cardiac trials keep failing, how AI could radically improve patient targeting, and why the future of precision medicine depends on collaboration between pharma, hospitals, software teams, and regulators. From clinical trial design to patient data ethics, the conversation explores what it will take to finally modernize cardiac drug development.
44 afleveringen
Reacties
0Wees de eerste die een reactie plaatst
Meld je nu aan en word lid van de The Innovation Blueprint community!